Invesco Ltd. Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Invesco Ltd. grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 33.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 957,893 shares of the biopharmaceutical company's stock after buying an additional 238,508 shares during the quarter. Invesco Ltd. owned 0.16% of Royalty Pharma worth $24,436,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of RPRX. Brooklyn Investment Group grew its holdings in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 876 shares during the period. Allworth Financial LP boosted its position in shares of Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares during the last quarter. Riverview Trust Co grew its stake in Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,186 shares in the last quarter. Fifth Third Bancorp raised its position in shares of Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 376 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Royalty Pharma has an average rating of "Buy" and an average target price of $42.50.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX traded up $0.34 during trading on Thursday, hitting $32.03. 716,268 shares of the company's stock were exchanged, compared to its average volume of 3,241,985. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The business's 50-day simple moving average is $32.54 and its 200 day simple moving average is $29.36. The company has a market cap of $18.46 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.75%. Royalty Pharma's payout ratio is 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.